ABBV 324
Alternative Names: ABBV-324Latest Information Update: 30 May 2025
At a glance
- Originator AbbVie
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Liver cancer; Non-small cell lung cancer
Most Recent Events
- 14 Apr 2025 Phase-I clinical trials in Liver cancer (Late-stage disease, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in Israel (IV) (NCT06858813)
- 14 Apr 2025 Phase-I clinical trials in Liver cancer (Late-stage disease, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in Puerto Rico (IV) (NCT06858813)
- 14 Apr 2025 Phase-I clinical trials in Liver cancer (Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in USA (IV) (NCT06858813)